Mercy BioAnalytics

Waltham, MA · Founded 2018 · Privately Held (backing)

Developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detection of cancer. Mercy BioAnalytics is based in Waltham, MA and was founded in 2018. It was valued at $122 million at its later-stage round in Mar 2023, the last priced event on record. It has raised $127 million across 1 recorded round; the latest was a $27.3 million early-stage round in Nov 2020.

PMV mark · valuation
$122.0M
Oct 2026
Priced at
its later-stage round
Mar 2023
Total raised
$127.3M
Last round
Early Stage VC
Nov 2020

Who backs Mercy BioAnalytics?

25 investors
InvestorType
New Enterprise AssociatesVenture capital
Jump CapitalVenture capital
Labcorp Venture FundVenture capital
Hatteras Venture PartnersVenture capital
iSelect FundVenture capital
Arben VenturesVenture capital
Perceptive AdvisorsHedge fund
Sozo VenturesVenture capital
AI FundOther
Flagship PioneeringVenture capital
+ 15 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Mercy BioAnalytics investors

25 investors are on record for Mercy BioAnalytics, including New Enterprise Associates, Jump Capital, Labcorp Venture Fund and Hatteras Venture Partners. By type, the record holds 9 venture capital firms and 1 hedge fund. The early-stage round in Nov 2020 drew 57 investors.

Free account
More of Mercy BioAnalytics with a free account
  • ·The complete investor list: 25 names
  • ·Watch Mercy BioAnalytics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 25 firms already write checks for companies like Mercy BioAnalytics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View